Cabaletta Bio Unveils Initial Rese-cel Data Without Preconditioning, Showcasing Biological Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 09 2025
0mins
Source: Newsfilter
Clinical Trial Results: In the RESET-PV trial, rese-cel demonstrated complete B cell depletion and significant clinical improvements in two of three patients with pemphigus vulgaris, with all patients remaining off immunomodulators and tapering steroids post-infusion.
CAR T Cell Expansion: The expansion of CAR T cells in patients without preconditioning was comparable to that seen in previous trials with preconditioning, suggesting the potential for a simplified treatment regimen.
Future Plans: Cabaletta Bio plans to expand patient enrollment in the RESET-PV trial and explore higher doses of rese-cel, while also considering the incorporation of no preconditioning regimens in other autoimmune disease trials.
Safety Profile: Rese-cel was generally well tolerated, with no severe adverse effects reported, and early clinical responses were observed based on improvements in the Pemphigus Disease Area Index (PDAI) scores.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like CABA with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on CABA
Wall Street analysts forecast CABA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CABA is 15.86 USD with a low forecast of 4.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 2.850
Low
4.00
Averages
15.86
High
30.00
Current: 2.850
Low
4.00
Averages
15.86
High
30.00
About CABA
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cabaletta Bio (CABA) Shares Surge 11% Following Insider Purchases
- Insider Purchases: Cabaletta Bio's General Counsel, Michael Gerard, purchased 6,600 shares on January 21, 2026, totaling $14,979, indicating strong confidence in the company's future prospects.
- CMO Acquisition: Chief Medical Officer Chang David J. acquired 8,800 shares at an average price of $2.26 per share, reflecting executive recognition of the company's value and optimism about future performance.
- President's Stake: President of Science & Technology, Binder Gwendolyn, bought 11,312 shares at an average price of $2.1891, bringing total ownership to 31,312 shares, which further bolsters market confidence in the company's outlook.
- Market Reaction: Following the insider purchases, Cabaletta Bio's shares surged 11% on Thursday, reflecting investor optimism regarding the company's future developments.
Continue Reading
High Roller Technologies Inc Closes Direct Offering, Raises $25 Million
- Successful Financing: High Roller Technologies Inc announced the completion of a registered direct offering of 1.89 million common shares at $13.21 per share, raising approximately $25 million in gross proceeds, significantly enhancing the company's liquidity to support future business expansion.
- Stock Surge: Following this announcement, High Roller’s shares jumped 29.6% to $10.21 in pre-market trading, reflecting strong market confidence in the company's growth potential and likely attracting more investor interest.
- Positive Market Reaction: The successful financing not only improves High Roller’s capital structure but also positions the company to gain a stronger competitive edge in the fiercely competitive online gaming market, aiding in further market share expansion.
- Strategic Growth Outlook: With this financing, High Roller Technologies can accelerate its strategic plans, including technological innovation and market expansion, which is expected to bring long-term growth opportunities and enhance shareholder value.
Continue Reading